A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.

Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Déclaration de conflit d'intérêts

The authors declare a conflict of interest. All authors have completed the ICMJE Form for Disclosure of Potential Conflicts of Interest. T. Miyazaki, K.I., K. Yanagihara, H.M., H. Kakeya, T. Matsumoto, and H. Yotsuyanagi have received lecture honoraria from Pfizer and MSD outside this work. N.T. has received lecture honoraria from MSD outside this work. T. Miyazaki, K.I., H.M., and H. Yotsuyanagi have received lecture honoraria from Gilead Sciences outside this work. T. Miyazaki has received a consultation fee from Pfizer and research grants from Pfizer and MSD outside this work. H.M. has received payments for expert testimony from Pfizer, MSD, and Gilead Sciences outside this work. H. Yotsuyanagi serves on the advisory board for Pfizer, MSD, and Gilead Sciences. The other authors have no competing interests. The sponsors and pharmaceutical companies had no role in the study design; collection, analysis, and interpretation of the data; and writing of the manuscript.